Initial Statement of Beneficial Ownership (3)

FORM 3	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES	OMB APPROVAL OMB Number: 3235-0104 Estimated average burden hours per response... 0.5
	Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person ^*

PRICE MICHAEL DENNIS

2. Date of Event Requiring Statement (MM/DD/YYYY) 12/4/2017

3. Issuer Name and Ticker or Trading Symbol

NOVELION THERAPEUTICS INC. [NVLN]

(Last) (First) (Middle)

C/O NOVELION THERAPEUTICS INC., 1800-510 WEST GEORGIA STREET

4. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director _____ 10% Owner
___ X ___ Officer (give title below) _____ Other (specify below)
Chief Financial Officer /

(Street)

VANCOUVER, A1 V6B OM3

(City) (State) (Zip)

5. If Amendment, Date Original Filed (MM/DD/YYYY)

6. Individual or Joint/Group Filing (Check Applicable Line)

_ X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock ⁽¹⁾	20000 ⁽²⁾	D

*Table II - Derivative Securities Beneficially Owned ( e.g.* , puts, calls, warrants, options, convertible securities)**
1. Title of Derivate Security (Instr. 4)	2. Date Exercisable and Expiration Date (MM/DD/YYYY)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivate Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security		6. Nature of Indirect Beneficial Ownership (Instr. 5)
Stock Option (Right to Buy)	⁽³⁾	11/27/2027	Common Stock	100000	$3.97 ⁽⁴⁾	D

Explanation of Responses:
(1)	These shares are issuable pursuant to a grant of restricted stock units. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer.
(2)	The restricted stock units vest in three equal annual installments beginning November 27, 2018.
(3)	This stock option award will vest and become exercisable in three equal annual installments beginning November 27, 2018.
(4)	Each option has an exercise price equal to the closing price of a common share of the Issuer on the Nasdaq Global Select Market on the date of grant.

Remarks:
See Exhibit 24.1 - Power of Attorney.

Reporting Owners
Reporting Owner Name / Address	Relationships
Reporting Owner Name / Address	Director	10% Owner	Officer	Other
PRICE MICHAEL DENNIS C/O NOVELION THERAPEUTICS INC. 1800-510 WEST GEORGIA STREET VANCOUVER, A1 V6B OM3			Chief Financial Officer

Signatures
/s/ Jennifer Fitzpatrick, attorney-in-fact		12/6/2017
^** Signature of Reporting Person		Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
*	If the form is filed by more than one reporting person, see Instruction 5(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note:	File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.